BWI - Company Full Bleed hero

Discover a new possible

We are Dedicated

To advancing AF treatment through focusing on three main areas: innovating new technology solutions, investing in research and publications to advance clinical understanding and improving education and awareness of AF among clinicians and the general public.

BW_landing_pages_HERO_icons1

Innovations

For over 20 years, we have been deeply committed to delivering innovative solutions designed to help clinicians reach more patients and heal more hearts.

BW_landing_pages_HERO_icons2

Research & Publications

With approximately 150 electrophysiology centres globally and a heritage of pioneering treatment in the field of EP, we are committed to advancing quality of care.

BW_landing_pages_HERO_icons3

Education & Awareness

We enable lifelong learning for those on the frontlines of care at J&J Institute and strive to deliver AF education and awareness among clinicians and the general public.

Inspired by Our Patients

On a Mission to Cure AF, innovation is at the heart of our organization and embedded in all we do. It fuels our discovery and development of new products and also extends to our collaborations, education and community efforts to bring new solutions to those in need. 

Atrial Fibrillation New Millennium Epidemic

 

Atrial Fibrillation is fast becoming one of the world’s most significant public health issues – affecting 14 millions of lives across EMEA and placing a critical burden on healthcare systems 1-3

Read More

Latest News

Comparing the Effectiveness of Different Catheter Ablation Technologies to Help Atrial Fibrillation (AF) Patients Live ‘Disease Free’

27 October 2020

Comparing the Effectiveness of Different Catheter Ablation Technologies to Help Atrial Fibrillation (AF) Patients Live ‘Disease Free’

 

Biosense Webster Launches CARTO® 3 System Version 7 and the CARTO PRIME™ Mapping Module to Advance Treatment of Complex Arrhythmias

27 August 2020

Biosense Webster Launches CARTO® 3 System Version 7 and the CARTO PRIME™ Mapping Module to Advance Treatment of Complex Arrhythmias

Commited to our Community

26 March 2020

Commited to our Community

Biosense Webster launches a two-pronged initiative to tackle the new millennium epidemic of Atrial Fibrillation

18 November 2019

Biosense Webster launches a two-pronged initiative to tackle the new millennium epidemic of Atrial Fibrillation

Contact Us

References

1. Zoni-Berisso M., L. C. D. (2014). Epidemiology of atrial fibrillation: European perspective.
Clinical Epidemiology 2014:6:213-220.
2. Ball et al. Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st Century. International Journal of Cardiology 167 (2013) 1807–1824. 
3. Data extracted by Global Burden Disease (GBD) Results Tool - GHDx website 24/10/2017

This site is published by Johnson & Johnson Medical NV/SA which is solely responsible for its content.

The minimum age for the website is 18. This site is intended for Healthcare Professionals from Europe, Middle-East and Africa where English is accepted in accordance with local laws and regulations, if applicable.

Important Information: Prior to use, refer to the “instructions for use” supplied with these devices for indications, contraindications, side effects, suggested procedure, warnings and precautions. As part of the Biosense Webster policy of continuous product development we reserve the right to change product specifications without prior notification.

Always verify catheter tip location using fluoroscopy or IC signals and consult the CARTO® 3 System User Guide regarding recommendations for fluoroscopy use.* Catheter advancement should be done under fluoroscopic guidance. Do not use excessive force to advance or withdraw the catheter when resistance is encountered. Careful catheter manipulation must be performed in order to avoid cardiac damage, perforation, or tamponade.

*Sporton S, Earley M, Nathan A, and Schilling R, Electroanatomic versus fluoroscopic mapping for catheter ablation procedures: A prospective randomized study. Journal of Cardiovascular Electrophysiology 2004;15,3:310-315

Product availability may differ in each country. Please contact us to find out further information.

Third party trademarks used herein are trademarks of their respective owners.

For full product details and precautions, please consult the IFU.

This publication is not intended for distribution outside of the EMEA region.

© Johnson & Johnson Medical NV/SA 2020. All rights reserved.
This site is published by Johnson & Johnson Medical NV/SA, which is solely responsible for its content.
This site is for visitors from Europe, Middle East and Africa.
The third party trademarks used herein are trademarks of their respective owners.

127436-191112 EMEA